Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Seagen Inc.
  6. News
  7. Summary
    SGEN   US81181C1045

SEAGEN INC.

(SGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Seagen : Q2 Loss Widens Amid Higher Revenue, Reaffirms Guidance -- Stock Up 2% After-Hours

07/29/2021 | 05:41pm EDT


ę MT Newswires 2021
All news about SEAGEN INC.
09/22SEAGEN : Guggenheim Adjusts Price Target on Seagen to $193 From $200, Maintains Buy Rating
MT
09/22SEAGEN : Goldman Sachs Adjusts Price Target on Seagen to $222 From $223, Maintains Buy Rat..
MT
09/22SEAGEN : SVB Leerink Adjusts Seagen's Price Target to $190 from $192, Keeps Outperform Rat..
MT
09/21SEAGEN : = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS..
PU
09/21SEAGEN INC. : Completion of Acquisition or Disposition of Assets, Financial Statements and..
AQ
09/21SEAGEN : Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK (tisotumab vedotin..
AQ
09/21SEAGEN : Presentation (opens in new window)
PU
09/21SEAGEN : and Genmab Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-..
PU
09/21U.S. Food and Drug Administration Grants Approval to TIVDAK
CI
09/21SEAGEN INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
More news
Analyst Recommendations on SEAGEN INC.
More recommendations
Financials (USD)
Sales 2021 1 503 M - -
Net income 2021 -420 M - -
Net cash 2021 2 613 M - -
P/E ratio 2021 -72,0x
Yield 2021 -
Capitalization 30 241 M 30 241 M -
EV / Sales 2021 18,4x
EV / Sales 2022 12,4x
Nbr of Employees 2 092
Free-Float 99,3%
Chart SEAGEN INC.
Duration : Period :
Seagen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SEAGEN INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 166,22 $
Average target price 184,61 $
Spread / Average Target 11,1%
EPS Revisions
Managers and Directors
Clay B. Siegall Chairman, President & Chief Executive Officer
Todd E. Simpson Chief Financial Officer
Vaughn B. Himes Chief Technical Officer
Roger D. Dansey Chief Medical Officer
Marc E. Lippman Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SEAGEN INC.-5.09%30 241
MODERNA, INC.335.15%177 895
LONZA GROUP AG33.16%61 006
IQVIA HOLDINGS INC.46.38%49 771
CELLTRION, INC.-20.75%31 824
PHARMARON BEIJING CO., LTD.76.77%25 533